Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes

Annals of Hematology

Volumn 89, Issue 7, 2010, Pages 671-679

  Wang, Hong ^a   Wang, XiaoQin ^a   Xu, XiaoPing ^a   Lin, GuoWei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Abnormal karyotype; Mean corpuscular volume; Myelodysplastic syndrome; Prognosis

Indexed keywords

HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; SURVIVAL; AGED; BLOOD; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; ERYTHROCYTE INDICES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 77953065244     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0912-6     Document Type: Article

References (32)

1. Tricot G, Vlietinck R, Boogaerts MA, Hendrickx B, De Wolf- Peeters C, Van den Berghe H, Verwilghen RL (1985) Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 60:19-32
2. Goasguen JE, Garand R, BizetM, Bremond JL, Gardais J, CallatMP, Accard F, Chaperon J (1990) Prognostic factors of myelodysplastic syndromes-a simplified 3-D scoring system. Leuk Res 14:255-262
3. Sanz GF, Sanz MA, Greenberg PL (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83:358-368
4. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59:425-433
5. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408
6. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323
7. Greenberg P, Cox C, LeBeauMM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring systemfor evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
8. Pfeilstocker M, Reisner R, Nosslinger T, Gruner H, Nowotny H, Tuchler H, Schlogl E, Pittermann E, Heinz R (1999) Crossvalidation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106:455-463
9. Takahashi M, Takahashi H, Aizawa Y, Koike T (1998) Usefulness of IPSS for the patients with refractory anemia. Am J Hematol 58:250-252
10. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302
11. Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24:983-992
12. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, Pittermann E, Pfeilstocker M (2001) Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution. Blood 98:2935-2941
13. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265-3270
14. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603
15. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M (2005) Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106:2633-2640
16. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596-1604
17. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510
18. Linman JW, Bagby GC Jr (1978) The preleukemic syndrome (hemopoietic dysplasia). Cancer 42:854-864
19. Bowen DT, Jacobs A (1989) Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects. J Clin Pathol 42:56-58
20. Tennant GB, Al-Sabah AI, Burnett AK (2002) Prognosis of myelodysplasic patients: Non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol 119:87-96
21. Matsuda A, Misumi M, Yoshida K, Yagasaki F, Ito Y, Kawai N, Bessho M (2003) Is macrocytosis a favourable prognostic factor in myelodysplastic syndrome patients without increased blasts? Br J Haematol 121:815-816
22. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP (2008) Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol 83:708-713
23. Mitelman F (ed) (1995) An international system for human cytogenetic nomenclature. S Karger, Basel
24. Brunning RD, Orazi A, Germing U et al (2008) World Health Organization classification of tumours. Pathology & genetics tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
25. Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, Seo EJ, Lee KH (2003) Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17:305-313
26. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, Cui J, Chen ZM, Cao Q, Yang G, Yao Y, Xia HL, Tong JH, Li JM, Chen J, Xiong SM, Shen ZX, Waxman S, Chen Z, Chen SJ (2005) Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 19:767-775
27. Shu XO, Gao YT, Brinton LA, Linet MS, Tu JT, Zheng W, Fraumeni JF Jr (1988) A population-based case-control study of childhood leukemia in Shanghai. Cancer 62:635-644
28. Deschler B, de Witte T, Mertelsmann R, Lubbert M (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 91:1513-1522
29. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, Locatelli F, MarchettiM,Morra E, Rebulla P, Visani G, Tura S (2002) Evidence- and consensus-based practice guidelines for the therapy of primarymyelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87:1286-1306
30. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90:2969-2977
31. Benitez J, Martinez Frejo C, Toledo C, Sanchez Fayos J, Ramos C (1987) Leukemic transformation in patients with the 5q-alteration: Analysis of the behavior of the 5q-clones in preleukemic to leukemic phases. Cancer Genet Cytogenet 26:199-207
32. Haase D, Fonatsch C, Freund M (1992) Karyotype instability in myelodysplastic syndromes-a specific step in pathogenesis preceding clonal chromosome anomalies. Leuk Lymphoma 8:221-228